🇺🇸 FDA
Patent

US 9006197

Compositions and methods for inhibiting expression of Eg5 and VEGF genes

granted A61KA61K31/713A61P

Quick answer

US patent 9006197 (Compositions and methods for inhibiting expression of Eg5 and VEGF genes) held by Alnylam Pharmaceuticals, Inc. expires Mon Apr 09 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Alnylam Pharmaceuticals, Inc.
Grant date
Tue Apr 14 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 09 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
27
CPC classes
A61K, A61K31/713, A61P, A61P35/00, A61P43/00